Edmolin.com

Informed Today Influential Tomorrow

Medicine

Gaelic Laboratories announces expansion – European Pharmaceutical Manufacturer

Gaelic Laboratories, a European CMO based in Ireland, has established a subsidiary in the UAE, enabling access to the Middle East market – both for Gaelic Laboratories and its marketing partners looking to access this rapidly-growing and lucrative region.

The Middle East pharma market was valued at $24 billion in 2023 and is predicted to reach a value of $32 billion by 2027, driven by growing populations, technological advancements, and government investments in healthcare infrastructure and access. The region’s potential has led many pharma companies to turn their attention to the Middle East, as reflected in the first CPHI Middle East event being held in Riyadh in December 2024. However, recent amendments to regulations in the Middle East included new requirements for the Marketing Authorization Holder (MAH) to have at least two local establishments for importing, distributing and marketing medical products. This presents a barrier to companies that don’t have a local presence in the region.

Gaelic Laboratories – a European CMO based in Ireland – has established a Commercial Arm in the UAE that enables the company to import, register, market and distribute medicines in the Middle East. With its newly opened Gaelic Drug Store LLC in Dubai, the company now has an infrastructure that enables it to market its own generic products in the region, and partner with other companies wanting to access the Middle East market.

“Gaelic Laboratories is a European manufacturer that has recognised the potential value of the Middle East market,” explains Brian Morrisey, General Manager of Gaelic Laboratories. “Our vision has always been to be a significant player in the generic pharma industry through the production of our own Beta-Lactam products, as well as contract manufacturing and testing services. Now, we are pleased to add a new service offering, as MAH partners for other high-quality pharma companies wanting to register and market their products in the Middle East.”

Adding to the company’s EU regulatory expertise at its headquarters in Ireland, he Gaelic Laboratories Scientific Office brings a full team of experts to manage access to the Middle East market, including regulatory consultants with a deep understanding of the requirements of local authorities. Gaelic Drug Store LLC then provides the company with a temperature-controlled warehouse with sufficient capacity to manage imported products – all of which are verified by an in-house pharmacist – for regional distribution.

Mohammed Bazara, Executive Committee Member, says “We had a lot of great meetings at CPHI Middle East last month, and our strategic investment in Dubai has been widely recognised as an opportunity for partnerships internationally. Our message is simple: Do you want to access the Middle East market? If so, Gaelic Laboratories can help!”

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *

Medicine

GSK’s RSV Vaccine Accepted Under Priority Review in USGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has accepted under priority review an application to extend the indication of GSK’s adjuvanted respiratory syncytial virus (RSV) vaccine to adults aged 50-59 who are at increased risk for RSV disease. If approved, GSK’s RSV vaccine would be the first vaccine available to help protect this population. Arexvy is currently approved in the US in adults aged 60 and over for the prevention of lower respiratory tract disease (LRTD) caused by RSV. The application is supported by positive results from a phase III trial [NCT05590403]4 evaluating the immune response and safety of GSK’s RSV vaccine in adults aged 50-59, including those at increased risk for RSV-LRTD due to underlying medical conditions. GSK used a Priority Review Voucher to reduce the US FDA review period of a supplemental Biologics License Application (sBLA) by four months. The Prescription Drug User Fee Act date, the FDA action date for their regulatory decision, is 7 June 2024. The burden of RSV disease in adults is likely to be underestimated due to lack of awareness, a lack of standardised testing, and under-detection in surveillance studies.5 People with underlying medical conditions, such as chronic obstructive pulmonary disease (COPD), asthma, chronic heart failure6 and diabetes,7 are at increased risk for RSV disease. RSV can exacerbate these conditions and lead to pneumonia, hospitalisation, or death.8